Every 8-K that SCYNEXIS, Inc. (SCYX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SCYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCYX filings page.
SCYNEXIS, Inc. entered into an Award/Contract with BARDA to support development of SCY-247, its second-generation fungerp antifungal candidate. BARDA’s potential total non-dilutive funding is up to $214 million. The initial base period commences in September 2026 and provides approximately $18.5 million to advance oral and intravenous SCY-247 into a Phase 2 study in patients with invasive candidiasis. The remaining potential award is subject to BARDA exercising up to six options, which could extend the contract for up to ten years.
If all options are exercised, the contract could fund SCY-247 development through New Drug Application submissions for treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients. It is a cost-share arrangement: BARDA supports eligible direct and general and administrative expenses, while SCYNEXIS expects to fund its share of near-term program costs within its existing operating plan. The company said its previously communicated SCY-770 development plans and projected cash runway into 2029 remain unchanged.
SCYNEXIS, Inc. (SCYX) announced that its Board appointed Steven K. Burke, M.D. as a director effective September 18, 2026, with his term running until the 2027 annual meeting, and named him to the Board’s Nominating and Corporate Governance Committee.
As a non-employee director, Dr. Burke will receive annual cash retainers and initial equity awards, including stock options and restricted stock units with multi‑year vesting schedules. The company highlights his more than 30 years of biopharmaceutical experience and nephrology-focused drug development background to support the advancement of SCY-770, its orphan-designated AMPK activator being developed for Autosomal Dominant Polycystic Kidney Disease.
SCYNEXIS, Inc. (SCYX) reported a planned transition in its finance leadership, with longtime Chief Financial Officer Ivor Macleod retiring and ceasing to serve as CFO, principal financial officer and principal accounting officer effective September 9, 2026, while remaining through October 9, 2026 to support a smooth transition. The company appointed Sanjay Subramanian as its new Chief Financial Officer effective September 9, 2026, also designating him as principal financial officer and principal accounting officer under an employment agreement.
Subramanian’s package includes a $500,000 annual base salary, a $20,000 sign-on bonus, and an annual performance bonus opportunity of up to 40% of base salary, plus a stock option for 100,000 shares of SCYNEXIS common stock at a $4.91 per-share exercise price vesting over four years. The agreement provides severance protections, including salary continuation, equity vesting acceleration, and COBRA benefits for nine months, or 18 months in connection with certain terminations within 12 months after a change of control.
SCYNEXIS, Inc. is registering the resale of up to 87,000,000 shares of common stock under an effective Form S-3, covering shares already held by selling stockholders and shares issuable from existing warrants.
The company also amended its certificate of incorporation to increase authorized stock from 23,750,000 to 65,000,000 shares, including an increase in authorized common stock from 18,750,000 to 60,000,000 shares. Stockholders approved this change at the June 25, 2026 annual meeting, held before a 1-for-8 reverse stock split that took effect on May 29, 2026. Certain warrants become exercisable following the authorized share increase, with pre-funded warrants priced at $0.0001 per share and common warrants at $1.20 per share, all on a pre-split basis.
SCYNEXIS, Inc. has approved and implemented a one-for-eight reverse stock split of its common stock, together with a reduction in authorized shares. Effective May 29, 2026, every eight issued and outstanding shares were combined into one share, and authorized common shares were reduced from 150,000,000 to 18,750,000 with no change in par value.
The reverse split applies proportionately to all stockholders and adjusts the share counts and, where applicable, exercise prices of stock options, restricted stock units and warrants. No fractional shares will be issued; holders entitled to fractions will receive cash instead. SCYNEXIS common stock is scheduled to begin trading on Nasdaq on a split-adjusted basis on June 1, 2026 under the symbol SCYX with a new CUSIP of 811292 309.
SCYNEXIS, Inc. held a special stockholder meeting where investors approved an amendment to its certificate of incorporation to implement a reverse stock split and decrease authorized shares. Stockholders cast 44,826,378 votes for the proposal, 6,708,960 against, and 102,965 abstaining, out of 79,442,633 shares entitled to vote.
Following this approval, the Board chose a one-for-eight reverse stock split ratio, effective May 29, 2026. Every 8 issued and outstanding shares of common stock will convert into 1 share, and authorized common shares will be reduced from 150,000,000 to 18,750,000 without changing par value.
The reverse split will proportionately affect all existing shares, as well as the share counts under equity compensation plans, options, RSUs, and warrants, with corresponding increases in option and warrant exercise prices. No fractional shares will be issued; holders entitled to fractions will receive cash instead. SCYNEXIS common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on June 1, 2026 under the existing ticker SCYX, with a new CUSIP number 811292 309.
SCYNEXIS, Inc. reported that board member Steven C. Gilman plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His term will end at that meeting, when his current directorship expires.
Until the 2026 annual meeting, Dr. Gilman will continue to serve as Chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. The company stated that his decision was not due to any disagreement regarding its operations, policies, practices, strategy, management, or Board.
SCYNEXIS, Inc. outlines a new rare-disease strategy built around SCY-770, a Phase 2–ready oral AMP-activated protein kinase activator for autosomal dominant polycystic kidney disease (ADPKD). The company acquired global rights to SCY-770 from Poxel with $8M upfront, up to $8M in development milestones, and up to $180M in commercial milestones, with no royalties.
SCYNEXIS reports a stronger balance sheet, highlighting approximately $56M in cash, cash equivalents and investments as of December 31, 2025 and about $40M of gross proceeds from a recent PIPE financing, extending its cash runway into mid-2029. Management plans to start a Phase 2 proof-of-concept study in ADPKD in Q4 2026, targeting an early efficacy readout in the second half of 2027, while continuing to advance antifungal candidate SCY-247 and royalty-bearing asset BREXAFEMME.
SCYNEXIS, Inc. entered into a private placement with institutional and accredited investors to raise approximately $40.0 million in gross proceeds. The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants, and accompanying common warrants to purchase up to 43,500,000 shares or pre-funded warrants.
Common shares plus warrants are priced at $0.92 per unit, and pre-funded warrant units at $0.9199. Common warrants carry a $1.20 exercise price and become exercisable after stockholder approval of an authorized share increase. If all warrants are exercised for cash, SCYNEXIS could receive up to an additional $52.2 million.
The company plans to use net proceeds for working capital and general corporate purposes. It estimates that existing cash, cash equivalents and marketable securities, together with anticipated net proceeds from this financing, will fund operations into mid‑2029, supporting development of programs including SCY‑770 for autosomal dominant polycystic kidney disease.
SCYNEXIS, Inc. entered into an Asset Purchase Agreement with Poxel SA to acquire Poxel’s direct AMP kinase activator research program, including lead compound PXL-770, now SCY-770, for rare kidney disease ADPKD. SCYNEXIS will make a one-time upfront payment of $8,000,000 within 30 days of the agreement’s effective date and may pay up to $188,000,000 in development and commercial milestone payments tied to clinical progress and annual net sales thresholds.
The deal also includes an exclusive, sublicensable, perpetual worldwide license to related Poxel intellectual property. SCY-770 has been tested in eight clinical trials with a favorable safety profile and is planned to enter a Phase 2 proof-of-concept study in ADPKD in Q4 2026, with an early efficacy readout anticipated in the second half of 2027. SCY-770 holds FDA Orphan Drug Designation, while SCYNEXIS continues to develop its antifungal franchise, including potential BREXAFEMME milestones up to $146 million and ongoing Phase 1 work on SCY-247.
SCYNEXIS (SCYX) entered a binding memorandum of understanding with GSK to amend their exclusive license, resolving the prior disagreement over the Phase 3 MARIO study of ibrexafungerp. SCYNEXIS will promptly wind down and terminate the MARIO study and will receive $22 million from GSK, plus an additional $2.3 million in connection with the wind-down and termination activities. SCYNEXIS will not receive additional milestone payments specifically tied to MARIO.
GSK reiterated its commitment to the broader collaboration, including commercialization of BREXAFEMME (ibrexafungerp tablets) for VVC and rVVC. SCYNEXIS continues to progress the transfer of the BREXAFEMME NDA to GSK by the end of 2025. GSK anticipates initiating FDA interactions in 2026 to discuss a U.S. relaunch for VVC and rVVC. Other potential milestones and royalties under the exclusive license remain unchanged.
SCYNEXIS (Nasdaq: SCYX) disclosed receipt of a Nasdaq bid-price deficiency notice on 20 Jun 2025 after its shares closed below $1.00 for 30 straight sessions.
The company has 180 days (until 17 Dec 2025) to lift the bid to at least $1 for 10 consecutive trading days. If unsuccessful, it may transfer to the Nasdaq Capital Market for another 180-day cure or face delisting, subject to appeal.
- Current Nasdaq Global Market listing remains unaffected.
- Management can pursue a reverse stock split or other actions to regain compliance.
- The notice heightens liquidity and funding risk and could deter institutional holders.